Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

Cancer Issues Author: Staff Editor Last Updated: Sep 7, 2017 - 10:06:33 PM



FDA Approves Lymphoseek to Help Determine the Extent of Head and Neck Cancer in the Body

By Staff Editor
Jun 13, 2014 - 12:21:24 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page

(HealthNewsDigest.com) - The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.

In 2013, Lymphoseek was approved to help identify lymph nodes closest to a primary tumor in patients with breast cancer or melanoma. Lymph nodes filter lymphatic fluid that flows from the body's tissues. This fluid may contain cancer cells, especially if the fluid drains a part of the body containing a tumor. By surgically removing and examining the lymph nodes that drain a tumor, a procedure called a biopsy, doctors can sometimes determine if a cancer has spread.

With today's approval, Lymphoseek can now be used to guide testing of lymph nodes closest to a primary tumor for cancer, called a "sentinel" lymph node biopsy, in patients with cancer of the head and neck. This new indication will allow for the option of more limited lymph node surgery in patients with sentinel nodes negative for cancer.

"For some patients with head and neck cancer, removal and pathological examination of lymph nodes draining a primary tumor is an important diagnostic evaluation," said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research. "To use Lymphoseek, doctors inject the drug into the tumor area and later, using a handheld radiation detector, find the sentinel lymph nodes that have taken up Lymphoseek's radioactivity."

For this new indication, Lymphoseek's safety and effectiveness were established in a clinical trial of 85 patients with squamous cell carcinoma of the lip, oral cavity, and skin. All patients were injected with Lymphoseek. Surgeons subsequently removed suspected lymph nodes-those identified by Lymphoseek and those based upon tumor location and surgical practice-for pathologic examination. Results showed that Lymphoseek-guided sentinel lymph node biopsy accurately determined if the cancer had spread through the lymphatic system.

The most common side effects identified in clinical trial was pain or irritation at the injection site.

Lymphoseek is marketed by Navidea Biopharmaceuticals, Inc. based in Dublin, Ohio.

For more information:



Top of Page

HealthNewsDigest.com

Cancer Issues
Latest Headlines


+ Number of Newly Diagnosed Cancer Patients Without Insurance Drops in First Year of ACA
+ Risk for Developing HPV-Related Throat Cancer Low
+ Nerves Drive Prostate Cancer
+ Rare Cancer Linked with Textured Breast Implants May Be Underreported, Misunderstood
+ How UV Rays Trigger Skin Cancer
+ Plant-Based Diet Converts Breast Cancer in Mice From Lethal to Treatable Form
+ Biology of Childhood Brain Tumor Subtypes Offers Clues to Precision Treatments
+ Discover New Blood Test That May Diagnose Breast Cancer
+ Bolstering Fat Cells Offers Potential New Leukemia Treatment
+ 1 in 9, or 11 Million, U.S. Men are Infected with Oral HPV



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions